Phaseline

Companies › Dispatch Biotherapeutics

Dispatch Biotherapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Apr 2046.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DISP-10
Combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (BCMA-dire
BCMAPhase 1Colorectal CancerApr 2046

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07544589DISP-10Phase 1Colorectal CancerOncologyApr 2046

Targets

BCMA (1)

Companies with the same targets

iCell Gene Therapeutics AbbVie Chongqing Precision Biotech Poseida Therapeutics Regeneron Pharmaceuticals Johnson & Johnson (Janssen) AstraZeneca Lakefront Biotherapeutics West Gracell Biotechnologies (Shanghai) Nexcella

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.